Peginterferon lambda-1a
Also known as: BMS-914143, IFN-λ1a, LAMBDA, Lambda IFN, PEG-IFN‑λ, Pegasys Lambda, Peginterferon lambda, RG7011
Source Peginterferon lambda-1a at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Pegylated recombinant interferon lambda‑1a designed for subcutaneous administration to treat viral hepatitis and other viral infections; not approved in major markets.
Mechanism of Action
Binds the heterodimeric IFN-λ receptor (IFNLR1/IL10R2) on epithelial cells, activating JAK‑STAT signaling and inducing antiviral ISGs.
Routes of Administration
Goals & Uses
- Chronic hepatitis C (HCV) treatmentAntiviral / HepatologyModerate
- Chronic hepatitis CAntiviralModerate
- Chronic hepatitis B (HBV) functional cureAntiviral / HepatologyModerate
- COVID-19 treatment (outpatient)Antiviral / Infectious DiseaseHigh
- Respiratory viral infections (influenza, RSV)Antiviral / RespiratoryLow
- Chronic hepatitis BAntiviral / HepatologyModerate
- Chronic hepatitis delta virus (HDV) treatmentAntiviral / HepatologyModerate
- COVID‑19Viral InfectionLow
Contraindications
- Severe hepatic impairment (Child‑Pugh C)Liver DiseaseModerate
- Hypersensitivity to interferons or PEGImmunologicHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Autoimmune hepatitisHepatic / AutoimmuneHigh
- Decompensated liver diseaseHepatic ImpairmentHigh
- Severe psychiatric disorders (untreated)PsychiatricHigh
Adverse Effects
- Elevated liver enzymes (ALT/AST flares)HepaticUncommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Elevated transaminasesHepaticUncommon
- Flu‑like syndromeSystemicCommon
- NeutropeniaHematologicUncommonLow neutrophil count
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Depression / Mood changesPsychiatricUncommon
- FatigueGeneralCommonLow energy or tiredness
- Injection‑site reactionLocalCommon
Drug Interactions
- Immunosuppressants (e.g., azathioprine, cyclosporine)Moderate
- Myelosuppressive agents (e.g., chemotherapy)Moderate
- Immunosuppressants (e.g., cyclosporine)Low
- CYP450 substrates (narrow therapeutic index)Low
- RibavirinModerate
Population Constraints
- Pediatric patients (<18 years)AgeRelative
- Pediatric patients (<12 y)AgeRelative
- Elderly (>75 y)AgeRelative
- Elderly (≥65 years)GeriatricRelative
- BreastfeedingReproductiveRelative
- Renal impairment (severe)RenalRelative
Regulatory Status
- European UnionInvestigationalEMA has not granted marketing authorization.
- United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
- United KingdomInvestigationalMHRA classifies as clinical trial material only.
Approved in Canada (2023) under the brand name Pegasys Lambda for COVID-19 outpatient treatment. Under regulatory review or investigational in other jurisdictions including the US. Has orphan drug designations for HDV in the US and EU. Not FDA-approved as of early 2024.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Peginterferon lambda-1a?
Pegylated recombinant interferon lambda‑1a designed for subcutaneous administration to treat viral hepatitis and other viral infections; not approved in major markets.
What is Peginterferon lambda-1a used for?
Peginterferon lambda-1a is educationally associated with: Chronic hepatitis C (HCV) treatment, Chronic hepatitis C, Chronic hepatitis B (HBV) functional cure, COVID-19 treatment (outpatient), Respiratory viral infections (influenza, RSV), Chronic hepatitis B, Chronic hepatitis delta virus (HDV) treatment, COVID‑19. Educational only — not medical advice.
How is Peginterferon lambda-1a administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Peginterferon lambda-1a?
Reported adverse effects include: Elevated liver enzymes (ALT/AST flares), Injection site reactions, Headache, Elevated transaminases, Flu‑like syndrome, Neutropenia, Nausea, Depression / Mood changes, Fatigue, Injection‑site reaction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Peginterferon lambda-1a?
Recorded contraindications: Severe hepatic impairment (Child‑Pugh C), Hypersensitivity to interferons or PEG, Pregnancy, Autoimmune hepatitis, Decompensated liver disease, Severe psychiatric disorders (untreated). Consult a qualified clinician before use.